Document is current
Any future updates will be listed below
-
Authors
Jung, Mijin
Pan, Xiaobei
Sweeney, Aoife
Passmore, Anthony P.
McGuinness, Bernadette
McAuley, Daniel F.
Beverland, David
Heslegrave, Amanda J.
Schott, Jonathan
Zetterberg, Henrik
Cunningham, Emma L.
Green, Brian D.
- License Information
-
More Information
Article History
Received: 23 April 2025
Accepted: 2 April 2026
First Online: 21 April 2026
Declarations
:
: Written informed consent was obtained from all participants and the study was approved by local ethical committee procedures (Office for Research Ethics Committees Northern Ireland; REC reference: 10/NIR01/5).
: Henrik Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).
